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Endosomeshocytic choriomeningitis virus (LCMV) into host cells was compared to the entry
of viruses known to exploit clathrin or caveolae/raft-dependent pathways. Pharmacological inhibitors,
expression of pathway-speciﬁc dominant-negative constructs, and siRNA silencing of clathrin together with
electron and light microscopy provided evidence that although a minority population followed a classical
clathrin-mediated mechanism of entry, the majority of these enveloped RNA viruses used a novel endocytic
route to late endosomes. The pathway was clathrin, dynamin-2, actin, Arf6, ﬂotillin-1, caveolae, and lipid raft
independent but required membrane cholesterol. Unaffected by perturbation of Rab5 or Rab7 and apparently
without passing through Rab5/EEA1-positive early endosomes, the viruses reached late endosomes and
underwent acid-induced penetration. This membrane trafﬁcking route between the plasma membrane and
late endosomes may function in the turnover of a select group of surface glycoproteins such as the
dystroglycan complex, which serves as the receptor of LCMV.
© 2008 Elsevier Inc. All rights reserved.Introduction
Many animal viruses exploit the endocytic machinery of their host
cells for infectious entry (Marsh and Helenius, 2006). After receptor
binding, they are internalized and transported in endocytic vesicles to
intracellular organelles from which they escape into the cytosol and
infect the cell. A large number of viruses, including Semliki Forest virus
(SFV), have been shown to make use of the classical clathrin-mediated
pathway to reach endosomes where the low pH triggers penetration
(Helenius et al., 1980). According to their pH-threshold of activation,
these viruses penetrate fromeither early (pH6.5–6.0) or late endosomes
(pH 6.0–5.0) (Kielian et al., 1986). Other viruses, such as Simian virus 40
(SV40), are known to use alternative, pH-neutral, caveolae/lipid-raft-
mediated pathways that carry them to caveosomes and the ER for
penetration (Parton and Richards, 2003). That viruses have evolved to
use distinct endocytic processes has made them valuable as tools for
characterizing the complex endocytic capabilities of mammalian cells.
In this study,wehave focusedon lymphocytic choriomeningitis virus
(LCMV), an enveloped, negative-stranded RNA virus of the arenavirus
family. LCMV persistently infects mice and can be transmitted from
these to humans, causing aseptic meningitis (Peters, 2006). Congenital
LCMV infection is consideredanunder-diagnosedhuman fetal teratogenH Zurich, Schafmattstrasse 18,
nius).
l rights reserved.(Barton and Mets, 2001). In addition to LCMV, the arenavirus family
comprises emerging pathogens such as Junin, Machupo, Lassa, Guanar-
ito, and Sabia viruses, which all cause severe hemorrhagic fevers when
transmitted to humans (Charrel and Lamballerie, 2003).
Like other arenaviruses, LCMV particles are pleomorphic in
appearance. They have a mean diameter of 86±21 nm, and they are
roughly spherical with spike-like projections formed by the envelope
glycoproteins (Neuman et al., 2005). The glycoproteins are trimeric
class I membrane fusion proteins, composed of fusion-mediating
transmembrane subunits (GP-2) associated with receptor-binding
subunits, GP-1 (Buchmeier, 2002; Eschli et al., 2006).
Themajor receptor for LCMV and other OldWorld arenaviruses has
been identiﬁed as α-dystroglycan, a highly glycosylated, peripheral
plasma membrane protein with afﬁnity for components of the
extracellular matrix (Cao et al., 1998). Receptor binding involves
lectin-like recognition of glycans on α-dystroglycan (Imperiali et al.,
2005; Kunz et al., 2004, 2005). Previous studies have established that
LCMV belongs to the acid-activated viruses: the virus is inactivated by
incubation inmildly acidic buffers, and fusion of LCMVwith liposomes
is induced by reduced pH (Di Simone and Buchmeier, 1995, 1994).
Furthermore, drugs interfering with organelle acidiﬁcation inhibit
infection (Borrow and Oldstone, 1994; Di Simone et al., 1994). After
escaping from an unidentiﬁed organelle by acid-induced membrane
fusion, LCMV replicates in the cytosol.
Our interest in LCMV was triggered by electron micrographs that
showed the incoming virus in smooth-walled pits in the plasma
Fig. 1. Electron microscopy on LCMV entry. LCMV inoculum was added to Vero cells for
1 h on ice and unbound virus washed away. The cell-bound viruses were immu-
nolabeled with 10 nm gold particles and allowed to enter the cells at 37 °C for 0 min
(A, upper left and middle panels), 10 min (A large panel and right column, B, C), or
30 min (D). The virus was efﬁciently labeled (A, upper left panel showing free LCMV
particles) and was observable in smooth and clathrin-coated structures of the host cell's
plasma membrane (A, B), as well as in intracellular vesicles and vacuoles (C, D). Of the
vacuoles, some were multivesicular (D). Scale bar: 200 nm.
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coats (Borrowand Oldstone,1994). By comparing the requirements for
LCMV infection with those for SFV and SV40, by silencing clathrin
genes, and by analyzing the process of infectious entry using a variety
of inhibitors and dominant-negative (DN) constructs, we analyzed the
entry route of LCMV in more detail.
Results
LCMV in smooth and coated structures by electron microscopy
To investigate the morphology of LCMV uptake, an inocculum of
strain LCMV-WE was added to Vero cells on ice, and the cell-bound
viruseswere immunolabeledwith 10 nm gold particles. After internal-
ization for different periods at 37 °C, the cells were ﬁxed and prepared
for transmission electron microscopy. As described previously for
the strain LCMV clone 13 (Borrow and Oldstone, 1994), entry was
asynchronous. Consistent with published images of LCMV clone 13
(Borrow and Oldstone, 1994), we observed gold-labeled LCMV-WE
particles closely bound to smooth segments of the plasma membrane,
in smooth-walled invaginations of the plasmamembrane, and close to
the plasma membrane in structures that may represent primary
endocytic vesicles (Fig. 1A). LCMV inside cytoplasmic vesicles and
larger sometimes multivesicular vacuoles represented later steps of
the entry process (Figs. 1C and D). However, LCMV-WE particles could
also occasionally be seen in clathrin-coated structures (Fig. 1B, com-
pare smooth and coated structures on the left and right panels). This
raised the possibility of the virus utilizing two endocytic pathways: a
clathrin-mediated and an uncoated pathway of endocytosis.
Infection is clathrin independent
To address the involvement of clathrin-mediated endocytosis (CME)
in LCMV-WE infection, we depleted HeLa cells of clathrin heavy chain
(CHC) using two different, non-overlapping siRNAs in parallel experi-
ments. With each siRNA, the protein level of CHC in the cultures was
reduced by 80–90% as assayed by Western blotting (Fig. 2A). By immu-
noﬂuorescence microscopy, a large fraction of the cells were devoid of
CHC staining on the plasma membrane although some intracellular
staining could be seen (Fig. 2B). Themajority of cells were unable to take
up transferrin (Fig. 2B, arrow heads), while a few still accumulated
intracellular transferrin (asterisks). We focused on the cells incapable of
internalizing transferrin and found, using immunostaining for the
nucleoprotein (NP) of LCMV, that these cells were efﬁciently infected
(Fig. 2B, quantiﬁcation Fig. 2C). In contrast, infectionwith Semliki Forest
virus, which uses the clathrin pathway exclusively, was strongly
inhibited in these cells (Figs. 2B and C). Control cells transfected with
an unrelated siRNA took up transferrin and were infected normally by
both viruses.
These results demonstrated that contrary to SFV, LCMV does not
require CME for productive infection of host cells. Thus, the smooth
vesicles observed by electron microscopy were apparently able to
support productive entry of the virus. The partial decrease in LCMV
infectivity in clathrin depleted cells was, however, consistent with the
possibility that a minority fraction of viruses did make use of CME for
infectious entry.
We also probed the inﬂuence of DN proteins commonly used to
inhibit CME. Eps15, an accessory protein, binds to the adaptor protein
complex AP-2. Expression of the deletion mutant Eps15 Δ95-295
interferes with AP-2 recruitment to the plasma membrane, impedes
the assembly of clathrin-coated pits, and prevents the endocytosis of
transferrin (Benmerah et al.,1999,1998). AP180 is the neuronal isoform
of CALM, the ubiquitously expressed clathrin assembly lymphoid
myeloid leukemia protein thought to play a regulatory role in clathrin
coat formation (Meyerholz et al., 2005). Overexpression of full-length
or truncated AP180/CALM inhibits endocytosis of EGF and transferrin
Fig. 2. LCMV infection is independent of clathrin. The CHC genewas silenced in HeLa cells using transfectionwith two different siRNAs, and the effect on LCMV and SFV infectionwas
determined. (A) Efﬁciency of clathrin heavy chain knockdownwas assayed byWestern blotting. (B) HeLa cells transfected with control or anti-CHC-siRNAs were infected with LCMV
or SFV (MOI ≤ 0.5) and incubated with ﬂuorescently labeled transferrin. Immunostaining against clathrin conﬁrmed reduced CHC levels. Transferrin uptake was found to be fully
blocked in a subpopulation of clathrin depleted cells (arrows), while other cells still accumulated transferrin (asterisks). LCMV infection occurred in both cell types, as detected by
staining against the viral NP. SFV infection was detected by immunostaining against envelope proteins and was strongly inhibited in the CME deﬁcient cells. Scale bar: 40 μm.
(C) Quantiﬁcation of panel B. The level of infection in cells incapable of transferrin uptake was normalized to the infection level in cells transfected with control siRNA. The absolute
infection level in the control samples was 20–50% for both viruses. Per virus and siRNA, three times 200 cells were counted in two independent experiments, error bars: SD.
23K. Quirin et al. / Virology 378 (2008) 21–33by interfering with clathrin-coated pit formation (Ford et al., 2001;
Tebar et al., 1999).
To conﬁrm the effect of Eps 15 and AP180 on CME in our experi-
ments, DN or control constructs were transiently expressed in Vero
cells as EGFP fusion proteins, and transferrin uptake was assayed by
microscopy. As expected, expression of the DN proteins, but not of
controls, inhibited transferrin uptake. However, the inhibition by
AP180 was only partial in some cells (Fig. 3A, asterisk). In parallel,
virus infection was assayed after addition of LCMV or SFV at low
multiplicity (MOI ~0.5) by immunostaining for newly synthesized
LCMV NP or SFV E1 and E2, respectively. Flow cytometry was used
here and in subsequent experiments to quantify the intensity of the
viral staining and the EGFP signal, with no crosstalk between the
channels (Fig. 3C, panels 1–3). To assess the effect of a given DN
protein rigorously and quantitatively, we deﬁned for each sample in
the histogram of the EGFP signal a “non-expressing” cell population
that was negative for EFGP-fusion protein and an “expressing” cell
population containing high levels of the protein. This is illustrated in
Fig. 3C (panels 4 and 7) using dynamin-2 K44A-EGFP. The infection
level within each populationwas quantiﬁed in a histogram of the virus
staining intensity (Fig. 3C, panels 5 and 6 for LMV; panels 8 and 9 for
SFV). To control for ﬂuctuations in cell number, we deﬁned the relative
infection level as the percentage of infected cells in the “expressing”cell population divided by the percentage of infected cells in the “non-
expressing” cell population. Absolute infection levels in non-trans-
fected control cells were 30–60%. LCMV infection was inhibited by
only 20% (DN Eps15) and 5% (DN AP180) consistent with a major
clathrin-independent mechanism of LCMV endocytosis also in Vero
cells (Fig. 3B). However, the DN constructs had only a partial inhibitory
effect on SFV. Since SFV infection strictly relies on CME, the results
suggested that SFV can make use of a clathrin-mediated pathway that
is independent of eps15. The apparent lack of AP2 dependence
implied by this result is not unprecedented among CME cargo (Conner
and Schmid, 2003; Hinrichsen et al., 2003; Lakadamyaliet al., 2006;
Motley et al., 2003). The partial effect of AP180 on SFV infection
probably reﬂects the “leakiness” of this inhibition protocol, as
reﬂected by the partial inhibition of transferrin uptake (cf. Fig. 3A,
asterisk).
Infection is dynamin-2 independent
The large GTPase dynamin-2 is involved in pinching off clathrin-
coated vesicles, caveolae, and certain types of lipid-raft-dependent
vesicles from the plasma membrane. Expression of DN dynamin
mutants inhibits these forms of endocytosis (Lamaze et al., 2001;
Oh et al., 1998; Sauvonnet et al., 2005; van der Bliek et al., 1993).
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transiently expressed as EGFP fusion proteins and the cells were
infected with LCMV or SFV at lowmultiplicity (MOI≤0.5). The fraction
of cells expressing a given fusion protein was determined by ﬂow
cytometry as described above (Fig. 3C). As expected, dynamin-2 K44Aexpression reduced SFV infection by 80%, but expression of wild-type
dynamin-2 had little effect in either Vero or HeLa cells (Figs. 3D and E).
In line with a clathrin-independent major entry route, LCMV infection
did not depend on dynamin-2 activity in either cell line. This ﬁnding
was not only consistent with the non-involvement of CME as a major
Fig. 4. LCMV infection is slightly enhanced upon mild cholesterol depletion. (A) Histograms of virus staining intensity before and after cholesterol depletion. (B) Left: Vero cells pre
treated with nystatin/progesterone were infected with SV40, LCMV, or SFV in the continued presence of the drugs. For LCMV, the drugs were replaced 180 min p.i. by NH4Cl
containing medium to block further penetration of the virus. The infection level was determined by immunostaining of viral proteins and ﬂow cytometry and was normalized to
samples where the inhibitors had been omitted. Right: Vero cells were infected in the presence of nystatin/progesterone as left, but the drugs were only present during incubation of
cells with inocula. Data shown are averages±SD of three independent experiments, each with triplicate samples. MOI ~0.5 for all viruses.
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the other lipid-raft-mediated pathways in LCMV infection. However,
since not all lipid-raft-mediated pathways are dynamin-2 dependent
(see, e.g., Damm et al., 2005; Sabharanjak et al., 2002), we next
adressed the potential involvement of lipid rafts in LCMV infection
more directly.
LCMV infection is lipid raft independent
The caveolae/raft-dependent pathways are highly sensitive to
cholesterol-depleting agents, whereas CME is only affected at high
doses (Anderson et al., 1996; Damm et al., 2005; Subtil et al., 1999).
To probe whether any step in LCMV entry prior to the pH-inducedFig. 3. LCMV infection is not affected by DN Eps15, DN AP180, or DN dynamin-2. (A) Transfer
constructs. Expression of the DN, but not the control constructs, inhibited transferrin uptake.
overexpression on SFV and LCMV infection, quantiﬁed by ﬂowcytometry. Data shown are ave
virus infection by ﬂow cytometry. The EGFP fusion protein of interest (shown here: dynamin
SFV (MOI ~0.5), and infection was detected by immunostaining against viral proteins. The E
staining of viral protein were detected independently with no crosstalk between the channel
LCMV infected sample; panels 7–9 show the same for an SFV infected sample. Two population
signal: A “non-expressing” population negative for EGFP and an “expressing” population
population was quantiﬁed in a histogram of the virus staining intensity (panels 5, 6 and 8, 9)
staining intensity above which a cell was infected. The effect of a given EGFP-fusion protein w
population expressing the protein divided by the infection level in the non-expressing cel
infection in Vero cells or (E) HeLa cells, quantiﬁed by ﬂow cytometry. Data shown are averapenetration in acidic organelles was sensitive to perturbation of lipid
rafts, we preincubated cells with increasing concentrations of nystatin
and progesterone. The cells were then infected with LCMV, SV40
(positive control: a virus that uses caveolae/raft pathways), or SFV
(negative control: a virus that uses CME) in the continued presence
of these inhibitors. The inhibitors were washed out 180 min post-
infection (p.i.) and replaced by the lysosomotropic agent NH4Cl to
prevent further penetration. As a membrane permeable weak base,
NH4Cl raises the endosomal pH nearly instantaneously (Ohkuma and
Poole,1978) and thereby intercepts any incoming viruses that have not
yet undergone the acid-induced membrane fusion step (Borrow and
Oldstone, 1994). Since NH4Cl is not toxic to cells, we could in this way
ensure better viability of the cells during the infection period.rin uptake in Vero cells transiently transfected with Eps15-EGFP, AP180-EGFP, or control
Inhibition by AP180was partial in some cells (asterisk). (B) Effect of DN Eps15 and AP180
rages of triplicate samples±SD. (C) Assay setup to determine the effect of DN proteins on
-2 K44A) was transiently expressed in Vero cells, the cells were infected with LCMV or
GFP signal used to quantify the expression level of the DN protein and the ﬂuorescent
s (panels 1–3). Panels 4–6 show histograms of EGFP and virus staining intensities for an
s of cells were selected in each sample based on predeﬁned intensity ranges of the EGFP
containing high levels of the construct. The percentage of cells infected within each
, using non-infected stained control samples (red traces) to deﬁne the threshold of virus
as expressed as normalized infection level, i.e., the ratio of the infection level in the cell
l population. (D) Effect of dynamin-2 wt and K44A overexpression on SFV and LCMV
ges of triplicate samples±SD. MOI ~0.5 for all viruses.
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and sequestration in a dose-dependent manner, while SFV infection
was not affected (Fig. 4B, left). That SV40 was inhibited indicated that
functional lipid-rafts were destroyed, while the lack of effect on SFV
infection indicated that the CME was functional and that early endo-
somes still contained enough cholesterol to support SFV fusion, a
cholesterol-dependent process (Phalen and Kielian, 1991). In contrast,
LCMV infectionwas slightly increased. If preincubation of the cells was
omitted and the cholesterol-depleting agents were added to the
inoculum only, no enhancement of LCMV infection could be detected
(Fig. 4B, right). Thus, the increase in LCMV infection was due to
cholesterol depletion of cellular membranes; i.e., it was not caused
by modiﬁcations of the viral envelope. We concluded that unlike
SV40, LCMV was not entering cells via pathways that required the
presence of lipid rafts. This was consistent with a caveolin-independent
mechanism.
Flotillin-1 and Arf6 independence of LCMV infection
A recent study has demonstrated that the lipid-raft-associated
protein ﬂotillin-1 is internalized with ﬂuid phase markers, GPI-
anchored GFP and cholera toxin, and colocalizes with these in
endosomal structures. The process is ﬂotillin-1 dependent and
independent of clathrin, and a connection with lipid-raft-mediated
pathways appears likely (Glebov et al., 2006). In order to address a
potential involvement of ﬂotillin-1 in LCMV entry, we investigated
whether incoming LCMV colocalizes with endogenous ﬂotillin-1 at
early time points of infection. Vero cells were treated at 4 °C with
LCMV (MOI ~50), warmed to 37 °C, incubated for different times, and
ﬁxed for immunostaining. Confocal ﬂuorescencemicroscopy was used
to localize the virus and to quantify its colocalization with marker
proteins using stringent, quantitative colocalization criteria (see
Materials and methods). The fraction of viruses colocalizing with
ﬂotillin-1 at 2, 5, and 10 min post-warming was very low (Fig. 5).Fig. 5. LCMV infection is independent of Flotillin-1. Entry of pre-bound LCMV into Vero cells
green. Bottom: same micrographs of ﬂotillin-1 as above, position of LCMV particles indicate
were determined by counting 200 virus particles in 3–5 cells per time point. Scale bar: 5 μmSince the level of colocalization was comparable to that observed
with a negative control (the subunit γ of COP-I, see Fig. 8C), it probably
reﬂected the background. We concluded that ﬂotillin-1 was unlikely
to be involved in LCMV entry.
The small GTPase Arf6 localizes to the plasma membrane and to
endosomal membranes, where it is involved in a variety of endocytic
processes (D'Souza-Schorey and Chavrier, 2006; Donaldson, 2003). In
its active, GTP-bound state, Arf6 can stimulate PI(4,5)P2 formation,
and it is involved in clathrin-coated pit formation (Krauss et al., 2003;
Paleotti et al., 2005). Furthermore, Arf6 has been reported to stimulate
lipid-raft-dependent trafﬁc of MHC I and of the GPI-anchored protein
CD59 to a distinct, Arf6-positive endosome in HeLa cells. The Arf6
compartment accumulates cargo molecules and ﬂuid phase markers
and is at early time points (2 min) distinct from the CME pathway.
Later, both pathways merge at the early endosome (Naslavsky et al.,
2003; Naslavsky et al., 2004).
To address a potential role of Arf6 in LCMVendocytosis,we examined
the effect of overexpression of a wild-type Arf6 and a constitutively
inactive, GDP-bound mutant form (Arf6 T27N) on LCMV infection.
Neither protein had any effect suggesting that LCMV entry is not
dependent on or regulated by Arf6 activation (Fig. 6A). We also could
not observe signiﬁcant colocalization between LCMV and transiently
expressed wild-type Arf6-EGFP by confocal microscopy (Fig. 6B).
LCMV infection is independent of macropinocytosis
To address a potential involvement of macropinocytosis, we
assessed the sensitivity of LCMV infection to cytochalasin D,
jasplakinolide, and amiloride. These agents inhibit macropinocytosis
by inhibiting actin polymerization or Na+/H+ exchange at the plasma
membrane (Swanson and Watts, 1995). By replacing the inhibitor of
interest against NH4Cl 3 h after initial infection as described above, we
focused again on inhibitory effects that the inhibitors might have in
the early steps of LCMV uptake and trafﬁc.by confocal microscopy. Top: LCMV in blue; endogenous, immunostained Flotillin-1 in
d by hollow circles to facilitate the colocalization analysis. Percentages of colocalization
.
Fig. 6. LCMV infection is independent of Arf 6. (A) Inﬂuence of expression of EGFP-labeled Arf-6 wt and Arf-6 T27N assayed by FACS analogous to Fig. 3C (MOI ~0.5). For both proteins,
the infection level was the virtually the same in the subpopulation expressing the protein as compared to the non-expressing control cells within the same sample. (B) Entry of pre-
bound LCMV into Vero cells expressing EGFP-labeled Arf-6 wt by confocal microscopy. Top: LCMV in blue; EGFP-labeled Arf-6 wt in green. Bottom: samemicrographs of Arf6 signal as
above, position of LCMV particles indicated by hollow circles to facilitate the colocalization analysis. Percentages of colocalization were determined by counting 200 virus particles in
3–5 cells per time point. Scale bar: 5 μm.
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(Fig. 7A). Instead of inhibiting, the F-actin depolymerizing agent cyto-
chalasin D and the F-actin stabilizing agent jasplakinolide caused a
clear increase in infection (Fig. 7A). This effect was likely caused by the
disruption of the cortical actin meshwork, an effect that could be
observed with both drugs (Fig. 7B). In line with this, we also observed a
pronounced increase in LCMV infection upon treatmentwith the F-actin
depolymerizing agent latrunculin A (data not shown). It is possible that
the cortical actin meshwork impedes LCMV entry by constituting a
physical barrier for vesiclemovementor by immobilizing factors needed
for LCMV endocytosis. Further, changes in cell shape upon drug treat-
ment might lead to shortening of the distance between the plasma
membrane and late endosomes, hence facilitating infection. Taken
together, the data indicated that LCMV-WE was not infecting cells via
macropinocytosis, which is consistent with previous data on LCMV
clone 13 (Borrow and Oldstone, 1994). In addition, the lack of inhibition
by jasplakinolide and latrunculin A was in marked contrast to the
requirements reported for caveolarentryof SV40 (Pelkmans et al., 2002).LCMV reaches late endosomes but bypasses early endosomes
Next, we asked to which acidic organelles LCMV was transported
inside the cell and where was the acid-induced penetration taking
place. First, we determined the kinetics of LCMV penetration using a
protocol previously employed for SFV (Helenius et al., 1980). Virus was
bound to cells on ice at low multiplicity (MOIb0.2), unbound virus
was washed off, after which the cells were rapidly warmed and
incubated for different time intervals at 37 °C before addition of NH4Cl
containing medium to block further penetration. As a benchmark, we
determined the penetration kinetics of two SFV strains that enter cells
via CME but have different pH thresholds for fusion. Wild-type SFV
penetrates at pHb6.2 in early endosomes, while the SFV fus-1 mutant
does so at pHb5.5 in late endosomes (Kielian et al., 1986). LCMV
penetration occurred within 10–30 min post-warming with a half
time of 16.4 min±2.1 min, compared to 6.2 min for wild-type SFV and
14.2 min for the mutant SFV fus-1 (Fig. 8A). With respect to the time
course of penetration, LCMV thus resembled fus-1.
Fig. 7. LCMV infection is independent of macropinocytosis. (A) Vero cells pre-treated
with amiloride (1, 20 μM), cytochalasin D (1, 20 μM), or jasplakinolide (50, 500 nM)were
infected with LCMV in the continued presence of the inhibitors. The drugs were
replaced 180 min p.i. by NH4Cl containing medium to block further penetration of the
virus. The infection level was determined by immunostaining of viral proteins and ﬂow
cytometry and was normalized to samples where the drugs had been omitted. Error
bars: SD of triplicate samples. (B) Vero cells expressing EGFP actin show a disrupted
cortical actin cytoskeleton after treatment with jasplakinolide or cytochalasin D.
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cells expressing the early endosome marker Rab5-EGFP or the late
endosome marker Rab7-EGFP were treated with LCMV (MOI ~50),
warmed to 37 °C, incubated for different time intervals, and ﬁxed for
immunostaining of LCMV using anti-NP. As before, confocal ﬂuores-
cence microscopy was used to visualize the virus and to quantify its
colocalization with marker proteins using stringent, quantitative
criteria (Figs. 8B and C; see Methods section). As a negative control,
we used colocalization with the immunostained subunit γ of COP I
and found that it did not exceed 3%.
Colocalization of LCMV with Rab5-EGFP exhibited a maximum of
10% at 5 min post-warming (Fig. 8C), decreasing rapidly thereafter to
background values within 40 min post-warming. In contrast,
colocalization of LCMV with Rab7-EGFP reached 15% within 20 min
post-warming and remained high (Fig. 8C). Similar colocalization time
courses were observed in HeLa cells for Rab5 and Rab7 (Fig. S1), as
well as for the endogenous markers EEA1 and LAMP-1 (Figs. 8E and F,
hatched lines) and transferrin (a contentsmarker for early endosomes,
see Fig. S2). These results indicated that a fraction of cell-associated
LCMV entered both early and late endosomes with a time course
similar to that of the typical CME cargo SFV (Vonderheit and Helenius,
2005). At the time of onset of membrane fusion, the majority of
viruses had reached late endosomes, which led us to conclude that
LCMV penetration most likely occurred upon arrival in late, Rab7 and
LAMP-1 containing endosomes.
Next, we compared the effect of DN Rab5 and Rab7 constructs on
LCMV infection with the effects on SFV and SFV fus-1 (Fig. 8D). As
expected, we found that SFV infection was partially inhibited by
expression of the GDP-locked, constitutively inactive Rab5 S34N, but
not by the corresponding Rab7 T22N construct (Sieczkarski and
Whittaker, 2003). In contrast, SFV fus-1 infection was inhibited byRab7 T22N (Fig. 8D). However, LCMV infection was reduced by 20%
only in the Rab5 S34N expressing cells, and it was even less affected by
Rab7 T22N, suggesting that only a minority population of the viruses
depended on these endosomal GTPases for transport to the organelle
of penetration.
The results raised the possibility that the major clathrin-inde-
pendent pathway of LCMV internalization by-passed early endosomes
altogether, and that the fraction of viruses found to colocalize with
early endosomes corresponded to the minor fraction that entered
through the clathrin-mediated pathway (Fig. 8C). Consistent with this,
we did not observe signiﬁcant colocalization of incoming LCMV with
the early endosome marker EEA1 when CME was blocked by siRNA
silencing of CHC in HeLa cells (Fig. 8E, solid lines). By comparing the
colocalization time courses of LCMVwith EEA1 and transferrin and by
demonstrating that the virus did not enter transferrin-containing
endosomes devoid of EEA1, we conﬁrmed EEA1 was a reliable marker
for the early endosomes that LCMV used after internalization via CME
(Fig. S2).
However, trafﬁcking of LCMV to LAMP-1-positive late endosomes
occurred normally and with comparable kinetics in cells treated with
anti-clathrin or control siRNA (Fig. 8F, solid vs. hatched lines). This
strongly suggested that the fraction of LCMV virions internalized by
the clathrin-independent route were indeed able to reach the late
endosomes without passing through early endosomes.
Discussion
LCMV is known to belong to the acid-activated viruses (Borrowand
Oldstone, 1994; Di Simone and Buchmeier, 1995; Di Simone et al.,
1994), but how it enters cells and in which intracellular organelle the
pH-induced membrane fusion occurs has remained unclear. Using
immunoﬂuorescence microscopy, we could demonstrate that LCMV-
WE entered both early and late endosomes. The acid-dependent step
occurred 10–20 min after warming coinciding with arrival of the virus
in Rab7 and Lamp-1-positive late endosomes. The time course of entry
is thus similar to that of inﬂuenza A virus and the fus-1 mutant of SFV,
both of which are also thought to penetrate from late endosomes
(Kielian et al., 1986; Sieczkarski and Whittaker, 2003). This was
consistent with LCMV's pH threshold of 5.8 for in vitro fusion with
liposomes and inactivation (Di Simone et al., 1994).
As schematically depicted in Fig. 9, our results indicated that LCMV-
WE uses two pathways to reach the late endosomes. We estimate that
about 20% of the incoming viruses are internalized via CME and
delivered ﬁrst to early endosomes and then to late endosomes. The rest
make use of a novel clathrin-independent route that also delivers the
viruses to late endosomes.
That a fraction of LCMV particles were internalized by CME was
evident both from the EM images and from the small but consistent
reduction in infection after silencing of clathrin heavy chain as well as
expression of dominant-negative constructs of Eps15, Rab5a, and
Rab7. The effects of dominant-negative constructs of Eps15 indicated
that the viruses that entered via CME made use of clathrin-coated pits
similar to those used by transferrin. In contrast, SFV, which was one of
the control viruses used in our study, required clathrin but not Eps15.
When clathrin heavy chains were silenced using siRNAs, incoming
LCMV entered late endosomes but were no longer observed in early
endosomes. Taken together, the data indicated that the LCMV particles
internalized via CME were routed along the standard pathway via
early endosomes to late endosomes, and that this involved both Rab5a
and Rab7.
That the majority of viruses were internalized by a pathway
independent of CME was demonstrated by electron microscopy; the
majority of viruses were located in plasma membrane pits and cyto-
plasmic vesicles devoid of a clathrin coat. Also, LCMV infection
was neither abolished by depletion of clathrin heavy chain nor by
overexpression of dominant-negative constructs of dynamin-2, Eps15,
Fig. 8. Endosomal transport of LCMV. (A) Penetration time course of LCMV, SFV, and SFV fus-1 in Vero cells. The viruses (MOI=0.2) were bound to cells on ice and then allowed to
internalize after rapid warming to 37 °C for different times before addition of NH4Cl containing medium to block further penetration and infection. The infection levels observedwere
normalized to the level in control cells. Error bars: SD of triplicate samples. (B) LCMV entry in Vero cells analyzed by confocal microscopy. Left: LCMV (red) and EGFP-Rab5 (green) at
10 min of internalization; middle: LCMV (red) and EGFP-Rab7 (green) at 40 min; right: LCMV (red) and COP I (green) at 5 min. (C) Quantiﬁcation of colocalization with cellular
markers. Per time point and marker, ca. 300 viruses in 7–10 cells were analyzed. Error bars: SE. (D) DN Rab5 and Rab7 reduce SFV or SFV fus-1 infection, but not LCMV infection.
Infectionwas analyzed as in Fig. 2, the infection levels of transfected cells were normalized to the infection level of non-transfected cells in the same sample (MOI ~0.5 for all viruses).
(E) Time course of colocalization with endogenous EEA1 in HeLa cells transfected with control siRNA or anti-CHC siRNA 1. (F) Time course of colocalization with endogenous LAMP-1
in HeLa cells transfected with control siRNA or anti-CHC siRNA. In panels E and F, only cells incapable to take up transferrin were analyzed for the CHC depleted samples. Per time
point and marker, ca. 100 viruses in 10–15 cells were counted. Error bars: SE.
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Fig. 9. Endocytic pathways exploited by LCMV. A minor fraction of LCMV enters cells via
the classical CME pathway: these viruses are taken up and transported to early
endosomes in a clathrin, dynamin-2, Eps15, and Rab5-dependent manner and depend
on Rab7 for arrival at late endosomes. The major fraction of LCMV arrives in late
endosomes with similar kinetics but makes use of a pathway that is independent on
clathrin, dynamin-2, Eps15, Rab5, and Rab7. These viruses bypass classical early
endosomes. This pathway is enhanced upon disruption of the cortical actin; it is
independent of macropinocytosis, lipid rafts, Arf-6 and ﬂotillin-1. Based on the effect of
CME inhibitors in infection experiments performed atMOI 0.5, we roughly estimate that
80% of LCMV enters cells via the CME-independent pathway.
30 K. Quirin et al. / Virology 378 (2008) 21–33AP180, or Rab5a. The loss of incoming viruses that passed through
EEA1-positive endosomes after silencing of clathrin heavy chain
suggested that cargo in this pathway was delivered to late endosomes
without passing through early endosomes.
The sensitivity of infection to different perturbations distinguished
themajor entry pathway from several clathrin-independent endocytic
processes described for the uptake of viruses, toxins, endogenous
ligands, and plasma membrane components (Mayor and Pagano,
2007). Infection was not affected by a dominant-negative dynamin-2
construct or by inhibitors of macropinocytosis. It was enhanced by
disruption of the actin cytoskeleton, and perturbation of cholesterol in
the plasma membrane indicated that functional lipid rafts were not
required. Arf6 and ﬂotillin-1 were, most likely, not involved.
This perturbationpatternwas not consistentwith anyof the various
pathways described in recent years, including (1) the caveolar pathway
used by SV40 in CV-1 cells (Anderson et al., 1996); (2) the lipid raft and
dynamin-dependent pathway used by the β-chain of interleukin-2
receptor, the γc cytokine receptor, autocrine motility factor, and
echovirus 1 (Lamaze et al., 2001; Pietiainen et al., 2004; Sauvonnet
et al., 2005); (3) the caveolin- and dynamin-independent, lipid-raft-
dependent pathway used by SV40 particularly in cells devoid of
caveolae (Damm et al., 2005); 4), the so-called GEEC pathway for the
internalization of GPI-anchored proteins (Sabharanjak et al., 2002);
and (5) the Arf6-dependent pathway for the internalization of class I
MHC antigens (Naslavsky et al., 2004). In addition, we could eliminate
macropinocytosis by the lack of F-actin dependence and the
insensitivity to amiloride (Swanson and Watts, 1995). Further, since
no colocalization between endogenous ﬂotillin-1 and LCMV could be
observed, the recently described ﬂotillin-1-dependent pathway
(Glebov et al., 2006; Payne et al., 2007) appeared not to be involved.
The lack of dependence on caveolin, Eps15, actin, and dynamin
was very recently reported for entry of LCMV clone 13 into Vero E6and CV1 cells (Rojek et al., 2007). The authors concluded like we did
that the virus uses a novel endocytic pathway. In apparent contra-
diction to our results, but in agreement with another recent
publication (Shah et al., 2006), they demonstrated that depletion of
cholesterol inhibits LCMV internalization and infection. Both groups
found a dose-dependent reduction in LCMV infection with 1–10 mM
methyl-β-cyclodextrin, a drug that extracts cholesterol from the
membrane rapidly and effectively. While this clearly demonstrated
that LCMV entry depends on cholesterol, unambiguous conclusions
about the involvement of lipid rafts and about the pathway of
endocytosis cannot be made because, at the concentrations used,
methyl-β-cyclodextrin may inhibit a variety of plasma membrane
processes including CME (Martin-Acebes et al., 2007; Rodal et al.,
1999; Subtil et al., 1999). Shah et al. (2006) also used a combination of
progesterone, which inhibits cholesterol synthesis, and the choles-
terol-sequestering agent nystatin (at a concentration 1000-fold higher
than we did), and found partial inhibition of infection. When Kunz
et al. employed nystatin and progesterone at a concentration 4-fold
higher than ours, they found partial inhibition of LCMV clone 13
infection, an observation that we could conﬁrm for LCMV-WE
(Fig. S3). By contrast, when we adjusted the nystatin/progesterone
concentrations to a lower level but sufﬁcient to block the infection of
the lipid-raft-dependent virus SV40 without effects on the entry of
SFV (which does not require cholesterol for endocytosis via CME but
requires cholesterol for membrane fusion in endosomes; Phalen and
Kielian, 1991), we found that LCMV infection was not inhibited but, in
fact, slightly enhanced. Barring effects due to differences in cell type
and virus strain, one may conclude from the combined data that
cholesterol is required for LCMV entry, but the type of lipid rafts
involved in SV40 entry is not necessary for productive entry. The
situation may resemble that found for type C food-and-mouth-
disease virus, which needs cholesterol but does not depend an lipid
rafts (for a discussion, see: Martin-Acebes et al., 2007). This possi-
bility is consistent with the observations of Shah et al. (2006) that
dystroglycan is not a lipid-raft-associated protein, and that it does not
move into lipid rafts when associated with LCMV (Shah, Peng, and
Carbonetto, 2006).
The clathrin-independent route taken by LCMV may share some
properties with pathways used by the plant toxin ricin and by
inﬂuenza A virus. Ricin binds to terminal galactose residues on
glycolipids and glycoproteins and is internalized in cholesterol-
depleted HeLa cells stably expressing dynamin-2 K44A (Rodal et al.,
1999). However, due to its broad receptor spectrum, this lectin is
endocytosed via virtually every pathway active in a given cell (Sandvig
et al., 2002) making it difﬁcult to deﬁne a single pathway without
ambiguity. Inﬂuenza A entry and infection occurs in part by CME, but a
considerable fraction of viruses seem to enter via smooth-walled
structures whose morphology resembles those involved in LCMV
internalization (Matlin et al., 1981). Inﬂuenza infects cholesterol-
depleted cells expressing DN Eps15 (Sieczkarski andWhittaker, 2002),
and live cell microscopy has revealed that a large fraction of the
viruses enters without associating with detectable amounts of
clathrin-EGFP (Rust et al., 2004). Although the alternative inﬂuenza
entry pathway seems to have some features in common with LCMV
entry, the dynamin-2, Rab5, and Rab7 dependence of inﬂuenza
infection (Roy et al., 2000; Sieczkarski and Whittaker, 2003) suggests
that the pathways are distinct. The examples of inﬂuenza virus and
SV40 show that LCMV is not unique among viruses in having the
capacity to use multiple pathways of endocytosis for entry. Such
pleiotropy may provide an advantage for viruses by improving the
chances for productive entry and broadening the cell speciﬁcity of
infection.
The demonstration of yet another variant of clathrin-independent
endocytosis in mammalian cells raises several questions to be
answered in future work. Is the pathway used by LCMV also used
for the internalization of physiological ligands and membrane
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molecular machinery mediates vesicle formation, ﬁssion, transport,
and targeting, and how is the pathway controlled? That the pathway
seems to provide a direct connection from the plasma membrane to
late endosomes is unique and may provide a clue as to a cellular
function: the pathway may serve to internalize and down-regulate
plasma membrane molecules and bound ligands that need to
circumvent early endosomes to avoid recycling. By binding to the
dystroglycan complex, LCMV and other arena viruses may have
evolved to exploit a receptor, the internalization and turnover of
which is controlled through this non-classical system. It is possible
that Lassa fever virus, a highly pathogenic arenavirus, which unlike
LCMV is strictly dependent onα-dystroglycan as a receptor, might rely
exclusively on this novel endocytic mechanism. Future investigations
with Arenaviridae and other viruses are likely to give exciting insights
into the expanding repertoire of endocytic mechanisms and at the
same time pave the way for the development of innovative anti-viral
strategies.
Materials and methods
Cell culture and viruses
Vero and HeLa cells (both fromATCC) weremaintained at 37 °C and
5% CO2 in MEM medium supplemented with Earle's salts, GlutaMAXI,
non-essential amino acids and 10% fetal calf serum. Infection of cells
was carried out in R-medium, i.e., RPMI-1640medium containing 0.2%
bovine serum albumin, 10 mM HEPES/NaOH (pH 6.8), and Penicillin-
Streptomycin. SFV wt, SFV fus-1, LCMV-WE, and SV40 were propa-
gated and titers were determined according to standard protocols. A
prototype tissue-culture-adapted SFV strain (SFV wt) and its mutant
SFV fus-1 were grown in BHK-21 cells (Kääriäinen et al., 1969; Kielian
et al., 1984). SV40 was propagated on CV-1 cells (Pelkmans et al.,
2001). LCMV-WE was originally obtained from F. Lehmann-Grube
(Heinrich Pette Institut, Hamburg, Germany) andwas propagated in L-
929 cells. This strain's GP sequence corresponds to the GP sequence
AJ297484 of LCMV-WE54 (Beyer et al., 2001). Of note, LCMV-WE54 has
been reported to strongly resemble LCMV clone 13 – the strain
preferentially used in other studies on LCMV entry (Borrow and
Oldstone, 1994; Rojek et al., 2007) – in terms of receptor binding
characteristics, cellular tropism, and disease phenotype in vivo (Sevilla
et al., 2000; Smelt et al., 2001; Kunz et al., 2004).
Antibodies and plasmids
The monoclonal antibodies VL-4 (rat) (Battegay et al., 1991) and
KL-53 (mouse) (Zeller et al., 1988) against LCMV-NP were puriﬁed
from hybridoma supernatant and directely labeled using NHS-
activated Alexa Fluor 647 (Molecular Probes, Invitrogen Corporation).
Mouse monoclonal antibody Pab 1605 against SV40 large T-antigen
was obtained from G. Brandner (Freiburg). Polyclonal serum against
SFV E1 and E2was raised in rabbit (Singh andHelenius,1992). Afﬁnity-
puriﬁed rabbit polyclonal anti-ﬂotillin-1 antibodywas kindly provided
by K. Simons and had been raised against a ﬂotillin-1 peptide. The
mouse monoclonal antibodies KL-25 (Bruns et al., 1983), Wen-1, and
Wen-4 (Seiler et al., 1998) against LCMV GP1 were puriﬁed from
hybridoma supernatants. Anti-EEA1 and anti-clathrin heavy chain
were from BD Transduction Laboratories, and anti-Lamp-1(clone
H4A3) was from Santa Cruz Biotechnology; all secondary antibodies
were bought from Molecular Probes (Invitrogen Corporation). Plas-
mids: human Eps15 Δ95/295-EGPF (Benmerah et al., 1999); human
Eps15 DIIIΔ2-EGFP (Benmerah et al., 1998); rat dynamin2(aa)-EGFP
and rat dynamin2(aa)K44A-EGFP (Cao et al., 2000); rat AP180 C-
terminal domain-EGFP (Ford et al., 2001); pEGFP-Rab5a (Sonnichsen et
al., 2000); Rab7-EGFP (Lebrand et al., 2002); and Arf6-EGFP (Naslavsky
et al., 2004).Transfection and siRNAs
For infection asssays, 2×105 Vero cells were plated on 4.5 cm2 dishes
and transfected ca.16 h later using 2 μg plasmid DNA and 10 μl Superfect
reagent (Qiagen). The cells were assayed 24 or 48 h (AP180) post-
transfection. For immunoﬂuorescence experiments, 106 exponentially
growing Vero cells were transfected 5–7 h before with 2.5 μg plasmid
DNA using the Amaxa Nucleofector, kit V, program A-24 (Amaxa, Köln,
Germany). Anti-Luciferase (CGUACGCGGAAUACUUCGA), anti-CHC1
(CCUGCGGUCUGGAGUC AAC) (Hinrichsen et al., 2003), and anti-CHC2
(AUCCAAUUCGAAGACCAAU) (Motley et al., 2003) were from Qiagen.
HeLa cells were transfected with siRNA using HiPerFect (Qiagen)
essentially as described (Motley et al., 2003). After a ﬁrst transfection
at day 1, the cells were split the following day to maintain exponential
growth, re-transfected at day 3, and split again at day 4. At day 5,
infection or entry assays were carried out, and a parallel cell culturewas
lysed in SDS-loading buffer for SDS–PAGE and subsequentWestern blot
analysis.
Infection and transferrin uptake assays
The inoculumwas prepared by diluting the appropriate amount of
virus stock in R-medium (composition see above). Cells at 80% con-
ﬂuence were washed with R-medium, a small volume (500 μl per
4.5 cm2,MOI ~0.5) of inoculumwas added and the cellswere incubated
under normal growth conditions. A non-infected control was mock
treated for later determination of the background signal. One hour p.i.
(LCMV, SFVwt, SFV fus-1) or 2 h p.i. (SV40), the inoculumwas replaced
by normal growth medium. The cells were further incubated for until
5 h (SFVwt), 6 h (SFV fus-1),12 h (LCMV), or 24 h (SV40) post-infection
to allow synthesis of viral proteins. For FACS analysis, samples were
trypsinized and ﬁxed in 4% formaldehyde in PBS. The cells were
resuspended in PBS containing 100 mM glycine and stored at 4 °C in
the dark until staining (see below). Samples for microscopy were ﬁxed
for 10–15 min in 4% formaldehyde in DMEM buffered with 10 mM
HEPES/NaOH pH 7, washed with PBS, and stored at 4 °C in the
dark until staining. If an infection experiment was to be combined
with a transferrin uptake assay, the cells were washed before ﬁxation
with DMEM and incubated for 10 min at 37 °C in DMEM containing
5 μg/ml ﬂuorescently labeled transferrin (Molecular Probes, Invitrogen
Corporation).
Pharmacological inhibitors
Nystatin (supplier: Sigma/solvent: DMSO/working concentration:
14, 7 μM) was combined with progesterone (Sigma/ethanol/16, 8 μM);
amiloride (Calbiochem/DMSO/1, 20 μM); cytochalasin D (Calbiochem/
DMSO/1, 20 μM); and jasplakinolide (Calbiochem/DMSO/50, 500 nM).
Except for cholesterol depletion with nystatin/progesterone (7 h
preincubation with the drugs in DMEM), the cells were preincubated
with the inhibitors in R-medium for 45 min before infection. The
inhibitors were present throughout the assay unless noted otherwise
and did not affect cell viability. To probe their effect on the early steps
of LCMV infection, the inhibitors were washed out 180 min post-
infection using MEM supplemented with Earle's salts, GlutaMAXI,
non-essential amino acids, 5% (v/v) fetal calf serum, 50 mM HEPES pH
7.6, and 20 mM ammonium chloride.
Penetration assays
Cells grown to 80% conﬂuence were incubated on ice and washed
with ice-cold R-medium. Ice-cold inoculum (MOIb0.2) was added and
the samples were incubated for 45 min on ice to allow binding of
the virus. Unbound virus was washed off with ice-cold R-medium. The
R-medium was replaced by normal growth medium containing
50 mM HEPES pH 7.6, and the samples were immediately transferred
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exchanged against normal growth medium containing 50 mM HEPES
pH 7.6 and 20 mM ammonium chloride. Samples were harvested as
described above.
Electron microscopy
Concentrated LCMV (108 pfu/ml) was bound to cells for 1 h on ice,
unbound virus was removed, and PBS containing 10% FCS (PBS-10)
was added. The cells were incubated on ice with antibodies against
LCMV GP1 (20 μg/ml KL-25, 10 μg/ml Wen-1, 5 μg/ml Wen-4) for 1 h,
washed in PBS-10, and incubated for 2 hwith 10-nm gold-labeled goat
anti-mouse antibodies on ice (Amersham Biosciences). The cells were
washed with PBS-10 and transferred to a 37 °C water bath for 5, 10, or
30 min before ﬁxation with 2% glutaraldehyde/2% osmium tetroxide
and sample preparation according to standard EM protocols.
FACS analysis
To detect viral proteins, ﬁxed cells were incubated in a dilution of
the primary antibody in permeabilization solution (PBS containing
0.1% saponin, 20mMEDTA, 0.02% sodiumazide, and 2% FCS). LCMV-NP
was stained using AlexaFluor 647-labeled VL-4 (20 μg/ml, 2 h at RT),
SV40 large T-antigen was stained using Pab1605 (20 μg/ml, 2 h at RT),
and SFV envelope proteins E1 and E2 were detected using rabbit
polyclonal serum (1:100, 2 h at RT). The samples were washed 3 times
in permeabilization solution and were stained with the appropriate
secondary antibodies where needed (10 μg/ml, 2 h at RT). Sample
analysis was performed on a FACS Calibur cytometer equippedwith an
FL-4 channel using CellQuest pro software (Becton Dickinson Immu-
nocytometry Systems). For experiments with DN proteins, 50,000 cells
per samplewere counted, 2000–5000 of which strongly expressed the
DN protein. For experiments with pharmacological inhibitors, 10 000
cells per samplewere counted. Dependingon the experiment, absolute
infection levels between 20% and 70% were observed.
Entry assays, transferrin uptake, and immunoﬂuorescence
microscopy
To saturate intracellular compartments with transferrin, cells were
washed once with DMEM, incubated for 10 min at 37 °C in DMEM
containing 5 μg/ml ﬂuorescently labeled transferrin (Molecular Probes,
Invitrogen Corporation) and transferred to ice. LCMV (MOI ~50) was
bound to cells on ice for 1 h, unbound virus was removed by washing
once with R-medium, R-medium containing 5 μg/ml ﬂuorescently
labeled transferrin was added, and the samples were shifted to a 37°
water bath to allow endocytosis of LCMV and transferrin. After varying
times at 37 °C, the samples were ﬁxed in 4% formaldehyde in DMEM
bufferedwith 10mMHEPES/NaOHpH7 for 15min at RTandwashed in
PBS. Cells were permeabilized in PBS containing 0.05% saponin, 10%
goat serum and 5% FCS, and LCMVwas stained over night at 4 °C using
VL-4 (5 μg/ml) followed by an appropriate goat anti-rat secondary
antibody. For co-stainings with mouse monoclonal antibodies, the
cells were ﬁrst incubated with the mouse antibody followed by a goat
anti-mouse secondary antibody. The samples were then ﬁxed in 4%
formaldehyde in PBS, residual formaldehyde was quenched by
washing in PBS containing 100 mM glycine, and LCMV was stained
over night at 4 °C using directly labeled VL-4 (20 μg/ml) and KL-53
(20 μg/ml). After washing, the samples were mounted on microscopy
slides using Shandon Immu-Mount (Thermo Electron, Dreieich,
Germany). Microscopy was performed at room temperature using an
inverted Zeiss laser scanning confocal microscope (model 510Meta,
Carl Zeiss MicroImaging, Inc.) equipped with a 100× Zeiss apochomat
objective (1.4 NA) and an Argon laser (458, 477, 488, 514) 30mW, HeNe
laser (543 nm) 1mW, orHeNe laser (633 nm) 5mW.All sampleswithin
one experiment were acquired with the same microscope settingsusing the LSM 510 software package (Carl Zeiss MicroImaging, Inc.).
Both LCMV staining protocols resulted in no background signal at all if
LCMV was omitted from the samples. Images were processed using
Adobe Photoshop for cropping and slight adjustments of intensity.
Colocalization analysis
Viruses were considered for analysis only if their apparent size was
between 0.5- and 1.2-fold of the calculated diameter of the airy disk. A
virus was considered to colocalize with a given marker if at least 50%
of the virus overlapped with the marker and if the maker signal
exhibited at the same time a clear local maximum below the virus.
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